Adaptive Biotechnologies Corp
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Seattle, State of Washington, on March 3, 2025.
| Adaptive Biotechnologies Corporation | |
|---|---|
| By: | /s/ Chad Robins |
| Chad RobinsChief Executive Officer | |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Chad Robins, his attorney-in-fact, with the power of substitution, for him in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Chad RobinsChad Robins | Chief Executive Officer and Director(Principal Executive Officer) | March 3, 2025 |
| /s/ Kyle PiskelKyle Piskel | Chief Financial Officer(Principal Financial Officer and Principal Accounting Officer) | March 3, 2025 |
| /s/ Michelle GriffinMichelle Griffin | Director | March 3, 2025 |
| /s/ Robert HershbergRobert Hershberg, PhD, MD | Director | March 3, 2025 |
| /s/ Peter NeupertPeter Neupert | Director | March 3, 2025 |
| /s/ Katey OwenKatey Owen, PhD | Director | March 3, 2025 |
| /s/ Michael Pellini | Director | March 3, 2025 |
| Michael Pellini, MD | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.